Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRILAT versus PRINIVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRILAT versus PRINIVIL.
ENALAPRILAT vs PRINIVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and cardiac workload.
Lisinopril is an angiotensin-converting enzyme inhibitor that decreases angiotensin II production, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
1.25 mg IV over 5 minutes every 6 hours; may increase to 5 mg IV every 6 hours if needed.
Initial dose 10 mg orally once daily; titrate to target dose of 20-40 mg daily based on blood pressure response.
None Documented
None Documented
Clinical Note
moderateEnalaprilat + Benzydamine
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benzydamine."
Clinical Note
moderateEnalaprilat + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat."
Clinical Note
moderateEnalaprilat + Droxicam
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam."
Clinical Note
moderateEnalaprilat + Loxoprofen
Terminal half-life: 35 hours (prolonged in renal impairment; accumulates with CrCl <30 mL/min)
Terminal elimination half-life is approximately 12 hours, with accumulation noted in renal impairment; effective half-life at steady state extends to 30-50 hours in patients with creatinine clearance <30 mL/min.
Renal: 60-80% unchanged; biliary/fecal: minimal (<10%)
Renal excretion accounts for approximately 60% of total clearance, primarily as unchanged lisinopril; fecal excretion accounts for negligible amounts.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen."